Aspirin, NSAID and risk of prostate cancer: Results from the REDUCE study - Abstract

Purpose: A recent meta-analysis showed aspirin was associated with reduced prostate cancer (PC) risk.

As anti-inflammatory medications lower PSA levels, whether these findings reflect reduced PC detection or lower PC risk is unknown. We tested the association between aspirin and non-aspirin NSAID on PC diagnosis in REDUCE, where all men received biopsies at 2- and 4-years largely independent of PSA. REDUCE tested dutasteride for PC risk reduction in men with a PSA of 2.5-10.0 ng/mL and a negative pre-study biopsy.

Experimental Design: We examined the association between aspirin, NSAID or both and total, low-grade (Gleason< 7), or high-grade (Gleason ≥7) PC vs. no PC using multinomial logistic regression among 6,390 men who underwent ≥1 on-study biopsy. Multivariable analyses were adjusted for age, race, geographic region, PSA, prostate volume, digital rectal examination, BMI, treatment arm, smoking, alcohol, statins, hypertension, diabetes and cardiovascular disease.

Results: Overall, 3,169 men (50%) were non-users, 1,368 (21%) used aspirin, 1,176 (18%) used NSAID, and 677 (11%) used both. In unadjusted models, aspirin was associated with reduced PC risk (OR=0.85, p=0.036). In multivariable analyses, aspirin was associated with reduced total PC risk (OR=0.81, p=0.015). Use of NSAID or NSAIDs and aspirin was not associated with total, low- or high-grade PC, though all ORs were < 1 (all p>0.08). Therefore, we created a dichotomous variable of aspirin and/or NSAID user vs. not. On multivariable analysis, the use of aspirin and/or NSAID was significantly associated with decreased total (OR=0.87, p=0.030) and high-grade (OR=0.80, p=0.040), but not with low-grade PC risk (OR=0.90, p=0.15).

Written by:
Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Adriole GL, Freedland SJ.   Are you the author?
Surgery, Duke University; Department of Biostatistics and Bioinformatics, Duke University School of Medicine; Urology, Mayo Clinic; Metabolic Pathways and Cardiovascular R&D unit, GlaxoSmithKline Inc; Urology, Washington University School of Medicine in St. Louis; Division of Urology, Department of Surgery, Duke University School of Medicine.  

Reference: Clin Cancer Res. 2014 Dec 17. pii: clincanres.2235.2014.
doi: 10.1158/1078-0432.CCR-14-2235


PubMed Abstract
PMID: 25520389

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe